IO Biotech, Inc. (IOBT) Stock Forecast
Data as of May 10, 2026Healthcare · Current price $0.01 (+30.65%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
IOBT vs Sector & Market
| Metric | IOBT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +3961.7% | +1706.0% | +16.4% |
| P/E Ratio | -0.01 | 3.30 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $14M | $14M | $14M | 2 |
| 2027-12-31 | $18M | $18M | $18M | 2 |
| 2028-12-31 | $54M | $54M | $54M | 2 |
| 2029-12-31 | $146M | $146M | $146M | 1 |
| 2030-12-31 | $212M | $212M | $212M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.29 | $-0.29 | $-0.29 | 1 |
| 2027-12-31 | $-0.31 | $-0.31 | $-0.31 | 1 |
| 2028-12-31 | $-0.25 | $-0.19 | $-0.13 | 2 |
| 2029-12-31 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2030-12-31 | $-0.04 | $-0.04 | $-0.04 | 1 |
Frequently Asked Questions
What is the analyst consensus for IOBT?
The consensus among 1 analysts covering IO Biotech, Inc. (IOBT) is Hold with an average price target of $0.50.
What is the highest price target for IOBT?
The highest analyst price target for IOBT is $0.50.
What is the lowest price target for IOBT?
The lowest analyst price target for IOBT is $0.50.
How many analysts cover IOBT?
1 analysts have issued ratings for IO Biotech, Inc. in the past 12 months.
Is IOBT a buy or sell right now?
Based on 1 analyst ratings, IOBT has a consensus rating of Hold (3.00/5) with a +3961.7% upside to the consensus target of $0.50.
What are the earnings estimates for IOBT?
Analysts estimate IOBT will report EPS of $-0.29 for the period ending 2026-12-31, with revenue estimated at $14M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.